Close Menu

NEW YORK – Bluebird Bio on Monday announced it was splitting its genetic disease and oncology business units into two separate publicly traded companies.

Bluebird will continue to focus on severe genetic disease, while the oncology business will be a new company. The plan has been approved by Bluebird's board of directors and the new oncology firm will be tax-free to shareholders once the Internal Revenue Service issues a favorable ruling. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.